RxDoctor Payments Data

Mustafa Khasraw, MD

Medical Oncology · New York, NYNPI 1235361353

Payments from drug & device makers

$284,416in general payments, 2019–2025

Across 138 payments — averaging $2060.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$171K
  • Biontech SE$102K
  • Janssen Global Services, LLC$5K
  • Novocure Inc.$4K
  • Daiichi Sankyo Inc.$2K
  • GSK$108
$84in research payments, 2019–2025

Across 1 payment — averaging $84.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Servier Pharmaceuticals LLC$84

What the payments were for

  • Consulting fees$10,85597%
  • Food & beverage$3113%

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie99$170,789
Biontech SE30$101,940
Janssen Global Services, LLC3$4,960
Novocure Inc.2$4,160
Daiichi Sankyo Inc.3$2,458
GSK1$108

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$284,416 in reported general payments places this provider in the 55th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York

Medicare billing

Part B allowed, 2024
$15,985
Medicare patients
60
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →